Meeting
2020 ASCO Virtual Scientific Program
The Integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).
Authors
Enrica Marchi
Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY
Enrica Marchi , Helen Ma , Francesca Montanari , Ahmed Sawas , Jennifer K Lue , Changchun Deng , Kareema T Whitfield , Sandra Klein , Luigi Scotto , Salvia Sanjay Jain , John Lister , Nora N Benanni , Mark A Francescone , Wonseog S Kim , Pier Luigi Zinzani , Owen A. O'Connor
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
03240211
Citation
J Clin Oncol 38: 2020 (suppl; abstr 8049)
DOI
10.1200/JCO.2020.38.15_suppl.8049
Abstract #
8049
Poster Bd #
382
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Prospective phase I multi-institutional trial of PD-1 blockade with pembrolizumab during concurrent chemoradiation for locally advanced, unresectable non-small cell lung cancer.
First Author: Salma K. Jabbour
Poster
2019 ASCO Annual Meeting
A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.
First Author: Drew W. Rasco
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
T-cell lymphoma secondary to checkpoint inhibitor (CPI) used for other malignancies.
First Author: Kartik Anand
Poster
2018 ASCO Annual Meeting
Exhausted CD8+ cells (Tex) to predict response to PD-1 therapy in estrogen receptor (+) hormone therapy resistant breast cancer predictive of response to immune checkpoint inhibitors after epigenetic priming.
First Author: Pamela N. Munster